ORASOL PLUS PREVIENE/RIDUCE LE MUCOSITI DA CHEMIO-RADIOTERAPIA

Data: 09 Ottobre 2015

Autore: Irene Giacomelli et al. Department of Radiation Oncology, University of Florence

Fonte: www.ncbi.nlm.nih.gov


Scarica l'allegato dello studio

Scarica il pdf

ORASOL PLUS PREVIENE/RIDUCE LE MUCOSITI DA CHEMIO-RADIOTERAPIA

Pubblicato su nutrition and cancer 2015, 67(8), 1249–1254

 

Oral Lapacho-Based Medication: An Easy, Safe, and Feasible Support to Prevent and/or Reduce Oral Mucositis During Radiotherapy for Head and Neck Cancer.

Abstract

The aim of our Phase II study is to demonstrate the benefits, safety, and tolerance of Orasol Plus, an easy and feasible Lapacho-based medication.  Orasol Plus is a nutritional, swallowable solution, useful to support the defenses of the oropharyngeal mucosa. Between January and June 2014, 40 consecutive adult patients affected by head and neck cancer were enrolled. Orasol Plus was administered 3 times a day from the first day till the end of radiotherapy. Primary endpoint was to evaluate tolerance and safety of Orasol Plus; secondary endpoint was to evaluate the effect of Orasol Plus on the incidence of treatment discontinuation.  Nearly all patients used Orasol Plus easily till the end of radiotherapy without interruptions. Only 11 (27.5%) patients developed oral mucositis (OM) Grade 2 and only 4 (10%) patients OM Grade 3, no patient developed OM Grade 4. No patient discontinued radiotherapy because of OM. Orasol Plus was well tolerated and the compliance of patients was optimal,  mainly due to the fact that it can be swallowed. Data from our study are encouraging and they need to be confirmed by a Phase III study.

15/03/2017 OPERA RIDUCE LE NEUROPATIE PERIFERICHE DA CHEMIOTERAPIA

di Isacco Desideri et al- University of Florence


20/10/2015 DIXENTIL PREVIENE LE DIARREE DA RADIOTERAPIA

di Daniele Scartoni et al. Department of Radiation Oncology, University of Florence


08/04/2013 ORASOL PREVIENE LE MUCOSITI IN PAZIENTI SOTTOPOSTI A TRAPIANTO AUTOLOGO

di A. Babic, F. Mariano, L. Orlando - European Institute of Oncology (Milan, IT)


05/11/2017 KUZIK SI DIMOSTRA EFFICACE NELLA PREVENZIONE DELL'EMICRANIA SENZA AURA

di E. Pucci, F. Solinas, C. Mostardini, M. Loiero, D. Soragna, R. Niego, R. Galante


08/05/2019 NAUGIN SI DIMOSTRA UTILE NELLA NAUSEA E DISGEUSIE DA RADIOTERAPIA

di Pierfrancesco Franco- Department of Oncology, Radiation Oncology, University of Turin


08/05/2019 KUZIK SI DIMOSTRA EFFICACE NELLA PREVENZIONE DELL' EMICRANIA SENZA AURA

di Vincenzo Tullo, Marcella Curone,Bruno Colombo,Gianni Allais,Davide Zarcone,Maria Gabriella Saracco,Gennaro Bussone


Prodotti in farmacia

disponibili in farmacia
e parafarmacia